Displaying 181–190 of 857 results
May 12, 2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
May 12, 2022
Foundation Fighting Blindness to Host VISIONS 2022 Conference
The national conference will be held on June 17–18, featuring sessions with the latest research advancements, practical adapting and thriving, and an opportunity to connect with the blind and low vision community.
May 10, 2022
Foundation Fighting Blindness to Host Online Continuing Medical Education (CME, COPE) Webinar: A Review of Gene Therapy for Inherited Retinal Disease
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
May 9, 2022
Cleanlogic Co-Founder’s Inspiration Comes From His Mom
In honor of Mother’s Day, we’re sharing a special Beacon Story featuring Isaac Shapiro, co-founder of Cleanlogic. Isaac’s mother, Bea, lost her vision at only seven years old but went on to become an entrepreneur and help others in the blind and visually impaired community through adaptive technology.
May 9, 2022
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Editas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
May 6, 2022
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
The study is an important step toward a clinical trial of the approach
May 2, 2022
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
The company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
Live Stream: XLRP-Patient Focused Drug Development
The live meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
XLRP-Patient Focused Drug Development
The goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
The Karen And Basil Petrou Legacy Education Initiative
The Basil and Karen Petrou Education Initiative is born of the Foundation’s commitment to helping individuals ensure their estates do the best they can for their loved ones and the causes they care about. Debuting this year, the program will offer ongoing resources to help individuals and families explore and learn about end-of-life plans and strategies.